Clinical trials anticipated for treating pancreatic cancer with cannabis

dmcc

A flavonoid of cannabis – FBL-03G – has been granted Orphan drug status by the United States Food and Drug Administration.

It is anticipated this will now lead to clinical trials with humans for treating pancreatic cancer with cannabis within the next few months.

Flavocure, a drug discovery and development company, was granted Orphan drug status to its lead drug candidate, the cannabis flavonoid Caflanone (FBL-03G), by the United States Food and Drug Administration (FDA), following the successful demonstration of its therapeutic efficacy in tumour progression in animals with pancreatic cancer.

Continue reading “Clinical trials anticipated for treating pancreatic cancer with cannabis”